Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment

doi:10.3748/wjg.v20.i2.486

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8094)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

518

WORD

373

HTML

4833

Figures (1-2)

304

Tables (1-2)

288

Sum=6316

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

940

Download

838

Sum=1778

Jan 14, 2014 (publication date) through Feb 27, 2025

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Jan 14, 2014; 20(2): 486-497
Published online Jan 14, 2014. doi: 10.3748/wjg.v20.i2.486

Table 2 Ongoing clinical studies that analyzed targeted therapy in combination with radiofrequency ablation

Number of clinical trials	Phase	Drug	Patients (n)	Timing	Primary endpoint
NCT01470495	Randomized study	Sorafenib (dose non specified)	200 TR	Together with RFA continuously	TTP
NCT00813293	II	Sorafenib (800 mg/d)	20	9 d before RFA	Effectiveness
SORAMIC trial	II	Sorafenib (dose non specified)	1500	After RFA or SIRT	Time to recurrence, OS
NCT01126645	II	Sorafenib (dose non specified)	1500	After RFA or SIRT	Time to recurrence, OS
STORM trial NCT00692770	III	Sorafenib(800 mg/d)	1114	After RFA continuously	RFS
NCT00728078	II-III	Thalidomide (150 mg/d)	200	After RFA for 6 mo	PFS, morbidity

TR: Target recruitment; RFS: Recurrence free survival; RFA: Radiofrequency ablation; TTP: Time to progression; OS: Overall survival; PFS: Progression free survival.

Citation: Ranieri G, Marech I, Lorusso V, Goffredo V, Paradiso A, Ribatti D, Gadaleta CD. Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment. World J Gastroenterol 2014; 20(2): 486-497
URL: https://www.wjgnet.com/1007-9327/full/v20/i2/486.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i2.486